grade
pharmaceutical primary standard
API family
riboflavin
manufacturer/tradename
USP
mp
290 °C (dec.) (lit.)
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
CC1=C(C)C=C(N(C[C@H](O)[C@@H]([C@H](O)CO)O)C(C2=N3)=NC(NC2=O)=O)C3=C1
InChI
1S/C17H20N4O6/c1-7-3-9-10(4-8(7)2)21(5-11(23)14(25)12(24)6-22)15-13(18-9)16(26)20-17(27)19-15/h3-4,11-12,14,22-25H,5-6H2,1-2H3,(H,20,26,27)/t11-,12+,14-/m0/s1
InChI key
AUNGANRZJHBGPY-SCRDCRAPSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Riboflavin USP reference standard for use in specified quality tests and assays.
Also used to prepare standard, and standard stock Riboflavin solution for assay, identification, and performance test according to the given below monographs and general chapters of United States Pharmacopeia (USP):
Also used to prepare standard, and standard stock Riboflavin solution for assay, identification, and performance test according to the given below monographs and general chapters of United States Pharmacopeia (USP):
- Riboflavin
- Riboflavin Tablets
- Water-Soluble Vitamins Preparation
- 〈481〉 Riboflavin Assay
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
Still not finding the right product?
Explore all of our products under Riboflavin
저장 등급
11 - Combustible Solids
flash_point_f
Not applicable
flash_point_c
Not applicable
Riboflavin Tablets
United States Pharmacopeia, 41(6), 3870-3870 (2017)
Water-Soluble Vitamins Preparation
United States Pharmacopeia, 45(5) (2021)
Olivier Richoz et al.
Investigative ophthalmology & visual science, 55(9), 5783-5787 (2014-07-24)
When treating peripheral ectatic disease-like pellucid marginal degeneration (PMD), corneal cross-linking with UV-A and riboflavin (CXL) must be applied eccentrically to the periphery of the lower cornea, partly irradiating the corneal limbus. Here, we investigated the effect of standard and